Boehringer Ingelheim

RETINAL HEALTH



Building on our knowledge and insights in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases, we have expanded our global research and development activities to address the serious medical need for effective treatment for eye diseases. Our goal is to transform the retinal health landscape by developing new treatments and technologies to prevent vision loss in people at risk of, and preserve or restore vision in those already with, retinal diseases.

Collaborations with academic institutions and biotech partners connect our scientists with experts and enable us to accelerate the delivery of much-needed new treatments. Our partnering interests offer various opportunities for collaboration to complement our pipeline and advance treatment and delivery including gene therapy approaches.

Core Indications:

- Geographic atrophy
- Wet age-related macular degeneration
- Diabetic macular ischemia
- Non-proliferative diabetic retinopathy
- Stargardt disease

Complementary Opportunities:

- Diabetic macular edema
- Retinal degeneration in glaucoma
- Myopic macular degeneration
- Proliferative diabetic retinopathy
- Chronic pan uveitis
- Retinitis pigmentosa
- Retinal vein occlusion

Contact:

Dr. Manuel Baader manuel.baader@boehringer-ingelheim.com

Dr. Andrew Whittle andrew.whittle@boehringer-ingelheim.com **Dr. Peter Benz** peter_michael.benz@boehringer-ingelheim.com